PL1871380T3 - Zastosowanie kombinacji związku prostaglandyny i inhibitora pompy protonowej w leczeniu zaburzeń żołądkowo-jelitowych - Google Patents

Zastosowanie kombinacji związku prostaglandyny i inhibitora pompy protonowej w leczeniu zaburzeń żołądkowo-jelitowych

Info

Publication number
PL1871380T3
PL1871380T3 PL06731937T PL06731937T PL1871380T3 PL 1871380 T3 PL1871380 T3 PL 1871380T3 PL 06731937 T PL06731937 T PL 06731937T PL 06731937 T PL06731937 T PL 06731937T PL 1871380 T3 PL1871380 T3 PL 1871380T3
Authority
PL
Poland
Prior art keywords
treatment
combined use
proton pump
gastrointestinal disorders
pump inhibitor
Prior art date
Application number
PL06731937T
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of PL1871380T3 publication Critical patent/PL1871380T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PL06731937T 2005-04-12 2006-04-11 Zastosowanie kombinacji związku prostaglandyny i inhibitora pompy protonowej w leczeniu zaburzeń żołądkowo-jelitowych PL1871380T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67023805P 2005-04-12 2005-04-12
PCT/JP2006/308001 WO2006109881A1 (en) 2005-04-12 2006-04-11 Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
EP06731937A EP1871380B1 (en) 2005-04-12 2006-04-11 Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders

Publications (1)

Publication Number Publication Date
PL1871380T3 true PL1871380T3 (pl) 2012-03-30

Family

ID=36685683

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06731937T PL1871380T3 (pl) 2005-04-12 2006-04-11 Zastosowanie kombinacji związku prostaglandyny i inhibitora pompy protonowej w leczeniu zaburzeń żołądkowo-jelitowych

Country Status (18)

Country Link
US (1) US8962688B2 (pl)
EP (1) EP1871380B1 (pl)
JP (2) JP5711442B2 (pl)
KR (2) KR20140069182A (pl)
CN (1) CN101198334B (pl)
AU (1) AU2006234632B2 (pl)
BR (1) BRPI0610557A2 (pl)
CA (1) CA2602812C (pl)
DK (1) DK1871380T3 (pl)
ES (1) ES2371658T3 (pl)
IL (1) IL186374A (pl)
NO (1) NO20075764L (pl)
NZ (1) NZ562763A (pl)
PL (1) PL1871380T3 (pl)
PT (1) PT1871380E (pl)
RU (1) RU2468800C2 (pl)
WO (1) WO2006109881A1 (pl)
ZA (1) ZA200709072B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114911B2 (en) * 2002-10-23 2012-02-14 Sucampo Ag Prostaglandin compounds for the treatment of obesity
JP5427029B2 (ja) * 2006-09-06 2014-02-26 スキャンポ・アーゲー 消化管の重炭酸分泌を促進するための方法および組成物
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
WO2009157397A1 (ja) * 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
BR112013026644A2 (pt) * 2011-04-19 2016-12-27 Sucampo Ag método para a modulação da atividade de citocina
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
KR20160015100A (ko) 2014-07-30 2016-02-12 미래파인켐 주식회사 프로스타글란딘 중간체의 제조방법
KR20170025682A (ko) 2015-08-31 2017-03-08 미래파인켐 주식회사 프로스타글란딘 유도체의 신규한 제조방법
CN107582556A (zh) * 2017-09-15 2018-01-16 成都泠汐尚品科技有限公司 一种治疗消化性溃疡的药物复方制剂
CN108051553A (zh) * 2017-12-29 2018-05-18 武汉轻工大学 一种仔猪肠道功能保护剂的筛选方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0688966B2 (ja) * 1987-01-28 1994-11-09 株式会社アールテック・ウエノ プロスタグランジンｅ類およびそれを含む抗潰瘍剤
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
CA2039420C (en) 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
ES2182088T3 (es) 1996-06-10 2003-03-01 Sucampo Ag Antagonista de la endotelina.
SE9804314D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New pharmaceutical formulation
DK1220849T3 (da) 1999-10-15 2004-09-27 Sucampo Ag Sammensætninger med bicykliske forbindelser og fremgangsmåde til stabilisering heraf
AU2001244727B2 (en) * 2000-04-06 2006-08-10 Sucampo Ag Bile secretion promoting composition
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
CA2458471C (en) 2001-08-31 2012-07-31 Sucampo Ag Prostaglandin analogs as chloride channel opener
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
NZ541110A (en) 2002-12-27 2008-11-28 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
WO2004064719A2 (en) 2003-01-24 2004-08-05 State Of Israel, Ministry Of Agriculture Synergistic compositions and methods for potentiating anti-oxidative activity
US20040248942A1 (en) 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid

Also Published As

Publication number Publication date
CA2602812A1 (en) 2006-10-19
IL186374A0 (en) 2008-03-20
WO2006109881A1 (en) 2006-10-19
US20070276006A1 (en) 2007-11-29
NO20075764L (no) 2008-01-14
JP5711442B2 (ja) 2015-04-30
ZA200709072B (en) 2008-11-26
BRPI0610557A2 (pt) 2010-06-29
EP1871380B1 (en) 2011-10-19
CA2602812C (en) 2014-11-18
DK1871380T3 (da) 2011-11-21
RU2007141655A (ru) 2009-05-20
KR20140069182A (ko) 2014-06-09
CN101198334A (zh) 2008-06-11
KR20070119753A (ko) 2007-12-20
IL186374A (en) 2013-05-30
CN101198334B (zh) 2013-02-06
EP1871380A1 (en) 2008-01-02
US8962688B2 (en) 2015-02-24
AU2006234632A1 (en) 2006-10-19
JP2008535774A (ja) 2008-09-04
AU2006234632B2 (en) 2011-10-27
KR101466980B1 (ko) 2014-12-01
ES2371658T3 (es) 2012-01-05
PT1871380E (pt) 2011-11-21
RU2468800C2 (ru) 2012-12-10
NZ562763A (en) 2010-12-24
JP2013121972A (ja) 2013-06-20

Similar Documents

Publication Publication Date Title
ZA200709072B (en) Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
AP2870A (en) Odcase inhibitors for the treatment of malaria
IL192691A0 (en) Hydantoin compounds for the treatment of inflammatory disorders
ZA200700384B (en) Hydantoin derivatives for the treatment of inflammatory disorders
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
PL1685834T3 (pl) Zastosowanie kwasu pinolenowego do leczenia otyłości
IL212985A0 (en) Therapeutic uses of inhibitors of rtp801
IL192692A0 (en) Compounds for the treatment of inflammatory disorders
HK1119577A1 (en) Compounds for the treatment of metabolic disorders
PT2056814E (pt) Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase
PL1912640T3 (pl) Zastosowanie inhibitora HDAC panobinostatu w leczeniu szpiczaka
ZA200805159B (en) Imidazole derivatives for the treatment of gastrointestinal disorders
IL181332A (en) A long-term treatment of human gastrointestinal disorders containing prostaglandin compound
SI2366393T1 (sl) Roflumilast za zdravljenje pljučne hipertenzije
HK1117737A1 (en) Use of adamantyl methoxydi phenyl propenoic acid for the treatment of acne
IL186286A0 (en) Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
WO2006042277A3 (en) Extended release compositions of proton pump inhibitors
IL179092A0 (en) Spiroderivatives for the treatment of hypertension
GB0422880D0 (en) The treatment of inflammatory disorders
GB0406017D0 (en) The treatment of inflammatory disorders
GB0406016D0 (en) The treatment of inflammatory disorders
GB2445888B (en) Treatment of hypertension
IL165438A0 (en) Use of amide derivative of ge2270 factor a3 for the treatment of acne
IL201439A0 (en) Use of hdac inhibitors for the treatment of melanoma
ZA200906906B (en) Use of HDAC inhibitors for the treatment of melanoma